Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

Cancer. 1974 Oct;34(4):985-92. doi: 10.1002/1097-0142(197410)34:4<985::aid-cncr2820340402>3.0.co;2-u.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Alopecia / chemically induced
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Digestive System / drug effects
  • Drug Evaluation
  • Female
  • Glycosides / therapeutic use
  • Hodgkin Disease / drug therapy
  • Humans
  • Injections, Intravenous
  • Leukemia / drug therapy*
  • Leukemia, Lymphoid / drug therapy
  • Leukemia, Monocytic, Acute / drug therapy
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukopenia / chemically induced
  • Lymphoma / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Non-Hodgkin / drug therapy
  • Male
  • Middle Aged
  • Pleural Effusion / drug therapy
  • Podophyllotoxin / administration & dosage
  • Podophyllotoxin / adverse effects
  • Podophyllotoxin / analogs & derivatives*
  • Podophyllotoxin / therapeutic use*
  • Thrombocytopenia / chemically induced

Substances

  • Glycosides
  • Podophyllotoxin